Toni Q Cao1, Karan Dixit1, Cesar Santa-Maria2, Priya Kumthekar1. 1. Department of Neurology, Northwestern University, Chicago, Illinois, USA. 2. Department of Oncology, Johns Hopkins University, Baltimore, Maryland, USA.
Abstract
BACKGROUND: Breast cancer is the second most common cancer associated with brain metastases. The purpose of this study was to identify factors that impact the time to brain metastases in breast cancer patients at a single institution. METHODS: Single institution retrospective study that captured all consecutive stage 2 and stage 3 breast cancer patients from 2003 to 2010. Patient characteristics analyzed included age, hormone status, HER2 receptor status, grade, stage, and time from breast cancer diagnosis to brain metastasis. RESULTS: A total of 1218 patients were eligible for the final analysis. 849 (69.7%) patients were ER+/HER2-, 90 (7.4%) were HER2+, and 279 (22.9%) were triple-negative (TN). Overall, 74 patients (6.1%) developed brain metastases over a median follow up time of 92 months. Median times to brain metastases for HER2+, TN, and ER+/HER2- patients were 20, 26, and 57 months, respectively. Multivariate analysis demonstrated that TN disease (HR = 2.043, P = .015), grade (HR = 1.667, P = .024) and stage (HR = 3.851, P < .001) were independent risk factors for earlier brain metastases. Median times to brain metastases were 34 and 52 months for stage 3 and 2 patients, and 30, 49, and 71 months for grade 3, 2, and 1 tumors, respectively. CONCLUSIONS: This single-institutional case series demonstrates that TN breast cancer, higher stage, and higher histologic grade are associated with earlier brain metastases in multivariate analysis. Additional prospective studies are warranted to investigate the impact of brain metastases screening on survival outcome in this high-risk defined group.
BACKGROUND: Breast cancer is the second most common cancer associated with brain metastases. The purpose of this study was to identify factors that impact the time to brain metastases in breast cancer patients at a single institution. METHODS: Single institution retrospective study that captured all consecutive stage 2 and stage 3 breast cancer patients from 2003 to 2010. Patient characteristics analyzed included age, hormone status, HER2 receptor status, grade, stage, and time from breast cancer diagnosis to brain metastasis. RESULTS: A total of 1218 patients were eligible for the final analysis. 849 (69.7%) patients were ER+/HER2-, 90 (7.4%) were HER2+, and 279 (22.9%) were triple-negative (TN). Overall, 74 patients (6.1%) developed brain metastases over a median follow up time of 92 months. Median times to brain metastases for HER2+, TN, and ER+/HER2- patients were 20, 26, and 57 months, respectively. Multivariate analysis demonstrated that TN disease (HR = 2.043, P = .015), grade (HR = 1.667, P = .024) and stage (HR = 3.851, P < .001) were independent risk factors for earlier brain metastases. Median times to brain metastases were 34 and 52 months for stage 3 and 2 patients, and 30, 49, and 71 months for grade 3, 2, and 1 tumors, respectively. CONCLUSIONS: This single-institutional case series demonstrates that TN breast cancer, higher stage, and higher histologic grade are associated with earlier brain metastases in multivariate analysis. Additional prospective studies are warranted to investigate the impact of brain metastases screening on survival outcome in this high-risk defined group.
Authors: B C Pestalozzi; D Zahrieh; K N Price; S B Holmberg; J Lindtner; J Collins; D Crivellari; M F Fey; E Murray; O Pagani; E Simoncini; M Castiglione-Gertsch; R D Gelber; A S Coates; A Goldhirsch Journal: Ann Oncol Date: 2006-04-07 Impact factor: 32.976
Authors: Fang Nie; Jian Yang; Song Wen; Yan-Li An; Jie Ding; Sheng-Hong Ju; Zhen Zhao; Hua-Jun Chen; Xin-Gui Peng; Stephen T C Wong; Hong Zhao; Gao-Jun Teng Journal: Cancer Date: 2012-04-17 Impact factor: 6.860
Authors: Amélie Darlix; Gaia Griguolo; Simon Thezenas; Eva Kantelhardt; Christoph Thomssen; Maria Vittoria Dieci; Federica Miglietta; PierFranco Conte; Antoine Laurent Braccini; Jean Marc Ferrero; Caroline Bailleux; William Jacot; Valentina Guarneri Journal: J Neurooncol Date: 2018-02-27 Impact factor: 4.130
Authors: Paul W Sperduto; Norbert Kased; David Roberge; Samuel T Chao; Ryan Shanley; Xianghua Luo; Penny K Sneed; John Suh; Robert J Weil; Ashley W Jensen; Paul D Brown; Helen A Shih; John Kirkpatrick; Laurie E Gaspar; John B Fiveash; Veronica Chiang; Jonathan P S Knisely; Christina Maria Sperduto; Nancy Lin; Minesh Mehta Journal: J Neurooncol Date: 2013-03-06 Impact factor: 4.130
Authors: Anurag Saraf; Christopher S Grubb; Mark E Hwang; Cheng-Hung Tai; Cheng-Chia Wu; Ashish Jani; Matthew E Lapa; Jacquelyn I S Andrews; Sierra Vanderkelen; Steven R Isaacson; Adam M Sonabend; Sameer A Sheth; Guy M McKhann; Michael B Sisti; Jeffrey N Bruce; Simon K Cheng; Eileen P Connolly; Tony J C Wang Journal: J Neurooncol Date: 2017-07-03 Impact factor: 4.130
Authors: Allison M Martin; Daniel N Cagney; Paul J Catalano; Laura E Warren; Jennifer R Bellon; Rinaa S Punglia; Elizabeth B Claus; Eudocia Q Lee; Patrick Y Wen; Daphne A Haas-Kogan; Brian M Alexander; Nancy U Lin; Ayal A Aizer Journal: JAMA Oncol Date: 2017-08-01 Impact factor: 31.777